Hemodialysis as a Risk Factor for Ceftriaxone‐Associated Pseudolithiasis in Adults

• Published in: Therapeutic apheresis and dialysis 2020-08, Vol.24 (4), p.393-399
• Main Authors: Ubukata, Masamitsu, Ohsawa, Isao, Suzuki, Hiroki, Asao, Rin, Nakamura, Yuya, Nishida, Hirofumi, Nakamura, Masayuki, Nitta, Kosaku, Goto, Yoshikazu, Gotoh, Hiromichi
• Format: Article
• Language: English
• Subjects: Adverse effect; Aged; Ceftriaxone; Ceftriaxone - adverse effects; Cholelithiasis - chemically induced; Cohort Studies; End‐stage renal disease; Female; Hemodialysis; Humans; Male; Pseudolithiasis; Renal Dialysis - adverse effects; Retrospective Studies; Risk Factors
• ISSN: 1744-9979; 1744-9987
• DOI: 10.1111/1744-9987.13445

Ceftriaxone‐associated biliary pseudolithiasis is common among children; however, there are only a few reports of pseudolithiasis in adult patients on HD. This retrospective cohort study included 278 adult patients on ceftriaxone therapy from 1 February 2016 to 1 September 2018. Pseudolithiasis was defined as a new development of sludge or stones in the gallbladder within 60 days of ceftriaxone therapy. After excluding patients with preexisting gallstones and a history of cholecystectomy, 113 patients on maintenance HD, and another 98 patients were enrolled as the HD and control group, respectively. Thirteen patients developed pseudolithiasis. Its incidence was significantly higher in the HD group than that in the control group. Multivariate logistic regression analyses showed that development of pseudolithiasis was significantly associated with HD and ceftriaxone dose. Therefore, HD in patients receiving ceftriaxone therapy appears to be associated with a risk of pseudolithiasis. These findings highlight the need for careful follow‐up.